Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

Core Insights - Pharvaris, a late-stage biopharmaceutical company, is focused on developing oral bradykinin B2 receptor antagonists for the prevention and treatment of hereditary angioedema (HAE) attacks [1][3] - The company announced the acceptance of two abstracts for oral presentation and ten for poster presentation at the upcoming 7th Bradykinin Symposium in Berlin, scheduled for September 5-6, 2024 [1] Presentation Details - Oral presentations include topics such as the Bradykinin Challenge Model and the efficacy of prophylactic treatment with Deucrictibant [1] - Poster presentations will cover various aspects of HAE treatment, including long-term safety and efficacy of Deucrictibant, and comparisons with standard care [1][2] Company Overview - Pharvaris aims to provide effective and well-tolerated treatment options for HAE through novel small molecules, with positive data from Phase 2 studies [3] - The company is currently enrolling participants for a pivotal Phase 3 study for on-demand treatment of HAE attacks and plans to initiate another pivotal Phase 3 study for prevention in the near future [3]